Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[177Lu]Lu-RTX-2358 and Immune Checkpoint Inhibitors in FAP-positive Metastatic NSCLC
NCT07689643Phase 1Recruiting
- Start
- Apr 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [177Lu]Lu-RTX-2358 in non-small cell lung cancer (NSCLC). Primary endpoint: Incidence and Severity of Treatment-Emergent Adverse Events. Started Apr 2026; status: recruiting.
02
Drugs
[177Lu]Lu-RTX-2358
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07689643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07689643.